share_log

Capricor Therapeutics Analyst Ratings

Capricor Therapeutics Analyst Ratings

Capricor 治療師評級
Benzinga ·  2023/08/15 06:35
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/15/2023 172.31% HC Wainwright & Co. → $18 Reiterates Buy → Buy
03/16/2023 172.31% HC Wainwright & Co. → $18 Reiterates → Buy
10/26/2022 126.93% Ladenburg Thalmann → $15 Initiates Coverage On → Buy
01/31/2022 172.31% HC Wainwright & Co. $14 → $18 Maintains Buy
10/11/2021 111.8% HC Wainwright & Co. $9 → $14 Maintains Buy
07/15/2019 87.59% HC Wainwright & Co. $3.5 → $12.4 Maintains Buy
12/31/2018 -47.05% HC Wainwright & Co. $8.6 → $3.5 Maintains Buy
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
08/15/2023 172.31% HC Wainwright & Co. → 18 美元 重申 購買 → 購買
03/16/2023 172.31% HC Wainwright & Co. → 18 美元 重申 → 購買
2022 年 10 月 26 日 126.93% 拉登堡塔爾曼 → 15 美元 啓動覆蓋開啓 → 購買
01/31/2022 172.31% HC Wainwright & Co. 14 美元 → 18 美元 維護 購買
2021 年 11 月 10 日 111.8% HC Wainwright & Co. 9 美元 → 14 美元 維護 購買
07/15/2019 87.59% HC Wainwright & Co. 3.5 美元 → 12.4 美元 維護 購買
12/31/2018 -47.05% HC Wainwright & Co. 8.6 美元 → 3.5 美元 維護 購買

What is the target price for Capricor Therapeutics (CAPR)?

Capricor Therapeutics（CAPR）的目標價格是多少？

The latest price target for Capricor Therapeutics (NASDAQ: CAPR) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $18.00 expecting CAPR to rise to within 12 months (a possible 172.31% upside). 3 analyst firms have reported ratings in the last year.

HC Wainwright & Co. 於2023年8月15日公佈了Capricor Therapeutics（納斯達克股票代碼：CAPR）的最新目標股價。這家分析公司將目標股價定爲18.00美元，預計CAPR將在12個月內升至12個月內（可能上漲172.31％）。去年有3家分析公司公佈了評級。

What is the most recent analyst rating for Capricor Therapeutics (CAPR)?

分析師對Capricor Therapeutics（CAPR）的最新評級是多少？

The latest analyst rating for Capricor Therapeutics (NASDAQ: CAPR) was provided by HC Wainwright & Co., and Capricor Therapeutics reiterated their buy rating.

Capricor Therapeutics（納斯達克股票代碼：CAPR）的最新分析師評級由HC Wainwright & Co. 提供，Capricor Therapeutics重申了他們的買入評級。

When is the next analyst rating going to be posted or updated for Capricor Therapeutics (CAPR)?

Capricor Therapeutics（CAPR）的下一個分析師評級何時公佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Capricor Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Capricor Therapeutics的最後一次評級是在2023年8月15日提交的，因此你應該預計下一個評級將在2024年8月15日左右公佈。

Is the Analyst Rating Capricor Therapeutics (CAPR) correct?

分析師對 Capricor Therapeutics (CAPR) 的評級正確嗎？

While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a reiterated with a price target of $0.00 to $18.00. The current price Capricor Therapeutics (CAPR) is trading at is $6.61, which is within the analyst's predicted range.

儘管評級是主觀的，將會發生變化，但最新的Capricor Therapeutics（CAPR）評級得到了重申，目標股價爲0.00美元至18.00美元。Capricor Therapeutics（CAPR）目前的交易價格爲6.61美元，在分析師的預測區間內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論